167 related articles for article (PubMed ID: 37523894)
1. Dimethyl alpha-ketoglutarate inhibits proliferation in diffuse intrinsic pontine glioma by reprogramming epigenetic and transcriptional networks.
Lee K; Yun S; Park J; Lee S; Carcaboso AM; Yi SJ; Kim K
Biochem Biophys Res Commun; 2023 Oct; 677():6-12. PubMed ID: 37523894
[TBL] [Abstract][Full Text] [Related]
2. Identification of Novel RAS Signaling Therapeutic Vulnerabilities in Diffuse Intrinsic Pontine Gliomas.
Koncar RF; Dey BR; Stanton AJ; Agrawal N; Wassell ML; McCarl LH; Locke AL; Sanders L; Morozova-Vaske O; Myers MI; Hamilton RL; Carcaboso AM; Kohanbash G; Hu B; Amankulor NM; Felker J; Kambhampati M; Nazarian J; Becher OJ; James CD; Hashizume R; Broniscer A; Pollack IF; Agnihotri S
Cancer Res; 2019 Aug; 79(16):4026-4041. PubMed ID: 31201162
[TBL] [Abstract][Full Text] [Related]
3. H3.3 K27M depletion increases differentiation and extends latency of diffuse intrinsic pontine glioma growth in vivo.
Silveira AB; Kasper LH; Fan Y; Jin H; Wu G; Shaw TI; Zhu X; Larson JD; Easton J; Shao Y; Yergeau DA; Rosencrance C; Boggs K; Rusch MC; Ding L; Zhang J; Finkelstein D; Noyes RM; Russell BL; Xu B; Broniscer A; Wetmore C; Pounds SB; Ellison DW; Zhang J; Baker SJ
Acta Neuropathol; 2019 Apr; 137(4):637-655. PubMed ID: 30770999
[TBL] [Abstract][Full Text] [Related]
4. Dual targeting of the epigenome via FACT complex and histone deacetylase is a potent treatment strategy for DIPG.
Ehteda A; Simon S; Franshaw L; Giorgi FM; Liu J; Joshi S; Rouaen JRC; Pang CNI; Pandher R; Mayoh C; Tang Y; Khan A; Ung C; Tolhurst O; Kankean A; Hayden E; Lehmann R; Shen S; Gopalakrishnan A; Trebilcock P; Gurova K; Gudkov AV; Norris MD; Haber M; Vittorio O; Tsoli M; Ziegler DS
Cell Rep; 2021 Apr; 35(2):108994. PubMed ID: 33852836
[TBL] [Abstract][Full Text] [Related]
5. Chaetocin-mediated SUV39H1 inhibition targets stemness and oncogenic networks of diffuse midline gliomas and synergizes with ONC201.
Xin DE; Liao Y; Rao R; Ogurek S; Sengupta S; Xin M; Bayat AE; Seibel WL; Graham RT; Koschmann C; Lu QR
Neuro Oncol; 2024 Apr; 26(4):735-748. PubMed ID: 38011799
[TBL] [Abstract][Full Text] [Related]
6. Histone tail analysis reveals H3K36me2 and H4K16ac as epigenetic signatures of diffuse intrinsic pontine glioma.
An S; Camarillo JM; Huang TY; Li D; Morris JA; Zoltek MA; Qi J; Behbahani M; Kambhampati M; Kelleher NL; Nazarian J; Thomas PM; Saratsis AM
J Exp Clin Cancer Res; 2020 Nov; 39(1):261. PubMed ID: 33239043
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic reprogramming and chromatin accessibility in pediatric diffuse intrinsic pontine gliomas: a neural developmental disease.
Mendez FM; Núñez FJ; Garcia-Fabiani MB; Haase S; Carney S; Gauss JC; Becher OJ; Lowenstein PR; Castro MG
Neuro Oncol; 2020 Feb; 22(2):195-206. PubMed ID: 32078691
[TBL] [Abstract][Full Text] [Related]
8. Signal Transduction in Diffuse Intrinsic Pontine Glioma.
Duchatel RJ; Jackson ER; Alvaro F; Nixon B; Hondermarck H; Dun MD
Proteomics; 2019 Nov; 19(21-22):e1800479. PubMed ID: 31328874
[TBL] [Abstract][Full Text] [Related]
9. DECIPHER pooled shRNA library screen identifies PP2A and FGFR signaling as potential therapeutic targets for diffuse intrinsic pontine gliomas.
Schramm K; Iskar M; Statz B; Jäger N; Haag D; Słabicki M; Pfister SM; Zapatka M; Gronych J; Jones DTW; Lichter P
Neuro Oncol; 2019 Jul; 21(7):867-877. PubMed ID: 30943283
[TBL] [Abstract][Full Text] [Related]
10. Potent anti-tumor efficacy of palbociclib in treatment-naïve H3.3K27M-mutant diffuse intrinsic pontine glioma.
Sun Y; Sun Y; Yan K; Li Z; Xu C; Geng Y; Pan C; Chen X; Zhang L; Xi Q
EBioMedicine; 2019 May; 43():171-179. PubMed ID: 31060906
[TBL] [Abstract][Full Text] [Related]
11. Microtubule-Targeting Combined with HDAC Inhibition Is a Novel Therapeutic Strategy for Diffuse Intrinsic Pontine Gliomas.
Ehteda A; Khan A; Rajakumar G; Vanniasinghe AS; Gopalakrishnan A; Liu J; Tsoli M; Ziegler DS
Mol Cancer Ther; 2023 Dec; 22(12):1413-1421. PubMed ID: 37683275
[TBL] [Abstract][Full Text] [Related]
12. Diffuse intrinsic pontine glioma (DIPG): A review of current and emerging treatment strategies.
Weisbrod LJ; Thiraviyam A; Vengoji R; Shonka N; Jain M; Ho W; Batra SK; Salehi A
Cancer Lett; 2024 May; 590():216876. PubMed ID: 38609002
[TBL] [Abstract][Full Text] [Related]
13. A kinome-wide shRNA screen uncovers vaccinia-related kinase 3 (VRK3) as an essential gene for diffuse intrinsic pontine glioma survival.
Silva-Evangelista C; Barret E; Ménez V; Merlevede J; Kergrohen T; Saccasyn A; Oberlin E; Puget S; Beccaria K; Grill J; Castel D; Debily MA
Oncogene; 2019 Sep; 38(38):6479-6490. PubMed ID: 31324890
[TBL] [Abstract][Full Text] [Related]
14. Re-programing Chromatin with a Bifunctional LSD1/HDAC Inhibitor Induces Therapeutic Differentiation in DIPG.
Anastas JN; Zee BM; Kalin JH; Kim M; Guo R; Alexandrescu S; Blanco MA; Giera S; Gillespie SM; Das J; Wu M; Nocco S; Bonal DM; Nguyen QD; Suva ML; Bernstein BE; Alani R; Golub TR; Cole PA; Filbin MG; Shi Y
Cancer Cell; 2019 Nov; 36(5):528-544.e10. PubMed ID: 31631026
[TBL] [Abstract][Full Text] [Related]
15. Combined treatment with CBP and BET inhibitors reverses inadvertent activation of detrimental super enhancer programs in DIPG cells.
Wiese M; Hamdan FH; Kubiak K; Diederichs C; Gielen GH; Nussbaumer G; Carcaboso AM; Hulleman E; Johnsen SA; Kramm CM
Cell Death Dis; 2020 Aug; 11(8):673. PubMed ID: 32826850
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of mutant PPM1D enhances DNA damage response and growth suppressive effects of ionizing radiation in diffuse intrinsic pontine glioma.
Akamandisa MP; Nie K; Nahta R; Hambardzumyan D; Castellino RC
Neuro Oncol; 2019 Jun; 21(6):786-799. PubMed ID: 30852603
[TBL] [Abstract][Full Text] [Related]
17. Design considerations of an IL13Rα2 antibody-drug conjugate for diffuse intrinsic pontine glioma.
Lian X; Kats D; Rasmussen S; Martin LR; Karki A; Keller C; Berlow NE
Acta Neuropathol Commun; 2021 May; 9(1):88. PubMed ID: 34001278
[TBL] [Abstract][Full Text] [Related]
18. TP53 wild-type/PPM1D mutant diffuse intrinsic pontine gliomas are sensitive to a MDM2 antagonist.
Xu C; Liu H; Pirozzi CJ; Chen LH; Greer PK; Diplas BH; Zhang L; Waitkus MS; He Y; Yan H
Acta Neuropathol Commun; 2021 Nov; 9(1):178. PubMed ID: 34732238
[TBL] [Abstract][Full Text] [Related]
19. Fimepinostat Impairs NF-κB and PI3K/AKT Signaling and Enhances Gemcitabine Efficacy in H3.3K27M-Diffuse Intrinsic Pontine Glioma.
Wang D; Yan K; Yu H; Li H; Zhou W; Hong Y; Guo S; Wang Y; Xu C; Pan C; Tang Y; Liu N; Wu W; Zhang L; Xi Q
Cancer Res; 2024 Feb; 84(4):598-615. PubMed ID: 38095539
[TBL] [Abstract][Full Text] [Related]
20. Differential Expression of Wilms' Tumor Protein in Diffuse Intrinsic Pontine Glioma.
Lee S; Kambhampati M; Yadavilli S; Gordish-Dressman H; Santi M; Cruz CR; Packer RJ; Almira-Suarez MI; Hwang EI; Nazarian J
J Neuropathol Exp Neurol; 2019 May; 78(5):380-388. PubMed ID: 30990879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]